Anthony J. Polverino Ph.D.
Net Worth

Last updated:

What is Anthony J. Polverino Ph.D. net worth?

The estimated net worth of Dr. Anthony J. Polverino Ph.D. is at least $4,113,696 as of 31 Aug 2021. He owns shares worth $436,804 as insider, has earned $36,632 from insider trading and has received compensation worth at least $3,640,260 in Zymeworks Inc..

What is the salary of Anthony J. Polverino Ph.D.?

Dr. Anthony J. Polverino Ph.D. salary is $606,710 per year as Chief Scientific Officer & Executive Vice President of Early Devel. in Zymeworks Inc..

How old is Anthony J. Polverino Ph.D.?

Dr. Anthony J. Polverino Ph.D. is 62 years old, born in 1963.

What stocks does Anthony J. Polverino Ph.D. currently own?

As insider, Dr. Anthony J. Polverino Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Zymeworks Inc. (ZYME) Chief Scientific Officer & Executive Vice President of Early Devel. 30,979 $14.1 $436,804

What does Zymeworks Inc. do?

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

ZYME logo
ZYME
Zymeworks Inc.
$14.1

Anthony J. Polverino Ph.D. insider trading

Zymeworks Inc.

Dr. Anthony J. Polverino Ph.D. has made only one insider trade between 2019-2021, according to the Form 4 filled with the SEC.

As of 31 Aug 2021 he still owns at least 30,979 units of ZYME stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Shares 4,900 $15 $73,500
Option
Stock Option (Right to Buy) 4,900 $15 $73,500
Option
Common Shares 2,500 N/A N/A
Option
Restricted Stock Unit 2,500 $34.82 $87,050
Sale
Common Shares 1,048 $34.95 $36,632
Option
Stock Option (Right to Buy) 27,500 N/A N/A
Option
Common Shares 27,500 N/A N/A

Zymeworks key executives

Zymeworks Inc. executives and other stock owners filed with the SEC:

  • Dr. Ali Tehrani (53) Co-Founder, Pres, Chief Executive Officer & Director
  • Dr. Anthony J. Polverino Ph.D. (62) Chief Scientific Officer & Executive Vice President of Early Devel.
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA (53) Executive Vice President of Bus. Operations & Chief Financial Officer
  • Ms. Kathryn O'Driscoll (61) Chief People Officer